{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:32:52Z","timestamp":1790609572329,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jinf.2025.106447","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:29:02Z","timestamp":1739878142000},"page":"106447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-2775","authenticated-orcid":false,"given":"Nadia","family":"Mazarakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-5837","authenticated-orcid":false,"given":"Zheng Quan","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-0942","authenticated-orcid":false,"given":"Eleanor","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Bright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyy","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Quah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Yung","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0599-8645","authenticated-orcid":false,"given":"Cattram","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien Anh Ha","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashini","family":"Dassanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Suryawijaya","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Justice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-8271","authenticated-orcid":false,"given":"Kerryn A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Mahanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"von Mollendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-6285","authenticated-orcid":false,"given":"Paul V.","family":"Licciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jinf.2025.106447_bib1","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jinf.2025.106447_bib2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-023-02228-4","article-title":"Predicting the efficacy of variant-modified COVID-19 vaccine boosters","volume":"29","author":"Khoury","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jinf.2025.106447_bib3","unstructured":"Statement on the antigen composition of COVID-19 vaccines. World Health Organisation; 2024. Available from: \u3008https:\/\/www.who.int\/news\/item\/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines\u3009. [Accessed: 26\/09\/2024]."},{"key":"10.1016\/j.jinf.2025.106447_bib4","unstructured":"FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently 402 Circulating Variants: FDA U.S. Food & Drug Administration; 2024. Available from: \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently\u3009. [Accessed: 01\/10\/2024]."},{"key":"10.1016\/j.jinf.2025.106447_bib5","unstructured":"WHO COVID-19 dashboard. World Health Organization; 2024. https:\/\/data.who.int\/dashboards\/covid19\/variants."},{"key":"10.1016\/j.jinf.2025.106447_bib6","unstructured":"Australia\u2019s vaccine agreements Australian Government, Department of Health and Aged Care; 2024. Available from: \u3008https:\/\/www.health.gov.au\/our-work\/covid-19-vaccines\/about-rollout\/vaccine-agreements#:\u223c:text=The%20Australian%20Government%20advises%20that%20the%20Novavax%20ancestral%20vaccine%20is,The%20new%20Novavax%20XBB\u3009. [Accessed: 01\/10\/2024]."},{"issue":"3","key":"10.1016\/j.jinf.2025.106447_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106119","article-title":"Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines","volume":"88","author":"Kalkeri","year":"2024","journal-title":"J Infect"},{"issue":"637","key":"10.1016\/j.jinf.2025.106447_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn8057","article-title":"Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection","volume":"14","author":"Evans","year":"2022","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jinf.2025.106447_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.jinf.2025.106447_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1313","article-title":"Comparison of seroconversion in children and adults with mild COVID-19","volume":"5","author":"Toh","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jinf.2025.106447_bib11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41591-022-02185-4","article-title":"A survey of COVID-19 vaccine acceptance across 23 countries in 2022","volume":"29","author":"Lazarus","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jinf.2025.106447_bib12","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1038\/s41467-022-34983-2","article-title":"Comparison of antibody responses to SARS-CoV-2 variants in Australian children","volume":"13","author":"Toh","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jinf.2025.106447_bib13","article-title":"SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity","volume":"3","author":"Richardson","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.jinf.2025.106447_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41564-023-01359-1","article-title":"Fc-gammaR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2","volume":"8","author":"Mackin","year":"2023","journal-title":"Nat Microbiol"},{"issue":"2","key":"10.1016\/j.jinf.2025.106447_bib15","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1093\/pubmed\/fdab011","article-title":"The use of dried blood spots for the serological evaluation of SARS-CoV-2 antibodies","volume":"44","author":"Toh","year":"2022","journal-title":"J Public Health (Oxf)"},{"issue":"10318","key":"10.1016\/j.jinf.2025.106447_bib16","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jinf.2025.106447_bib17","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41591-023-02517-y","article-title":"Original SARS-CoV-2 monovalent and Omicron BA.4\/BA.5 bivalent COVID-19 mRNA vaccines: phase 2\/3 trial interim results","volume":"29","author":"Chalkias","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jinf.2025.106447_bib18","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2666-5247(23)00012-5","article-title":"Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study","volume":"4","author":"Regev-Yochay","year":"2023","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.jinf.2025.106447_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41541-023-00693-z","article-title":"Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants","volume":"8","author":"Lyke","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"41","key":"10.1016\/j.jinf.2025.106447_bib20","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1016\/j.vaccine.2023.07.056","article-title":"Immunogenicity and safety of NVX-CoV2373 as a booster: a phase 3 randomized clinical trial in adults","volume":"41","author":"Raiser","year":"2023","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.jinf.2025.106447_bib21","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJMoa2201688","article-title":"Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"386","author":"Magen","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jinf.2025.106447_bib22","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2025.106447_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071113","article-title":"Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study","volume":"377","author":"Gazit","year":"2022","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jinf.2025.106447_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI167955","article-title":"Durability of immune responses to mRNA booster vaccination against COVID-19","volume":"133","author":"Arunachalam","year":"2023","journal-title":"J Clin Invest"},{"issue":"24","key":"10.1016\/j.jinf.2025.106447_bib25","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jinf.2025.106447_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jinf.2023.04.012","article-title":"Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial","volume":"87","author":"Liu","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2025.106447_bib27","first-page":"6","article-title":"The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old","volume":"89","author":"McLeod","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2025.106447_bib28","article-title":"Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial","volume":"42","author":"Batmunkh","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"10.1016\/j.jinf.2025.106447_bib29","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"8","key":"10.1016\/j.jinf.2025.106447_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24657","article-title":"Association of receiving a fourth dose of the BNT162b vaccine with SARS-CoV-2 infection among health care workers in Israel","volume":"5","author":"Cohen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.jinf.2025.106447_bib31","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41591-022-01832-0","article-title":"Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60\u2009years","volume":"28","author":"Arbel","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jinf.2025.106447_bib32","article-title":"Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study","volume":"34","author":"Lazar Neto","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"12","key":"10.1016\/j.jinf.2025.106447_bib33","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S2213-2600(23)00306-5","article-title":"Effectiveness of BNT162b2 BA.4\/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study","volume":"11","author":"Tartof","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jinf.2025.106447_bib34","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1093\/infdis\/jiad519","article-title":"The Novavax heterologous coronavirus disease 2019 booster demonstrates lower reactogenicity than messenger RNA: a targeted review","volume":"230","author":"Marchese","year":"2024","journal-title":"J Infect Dis"},{"issue":"10318","key":"10.1016\/j.jinf.2025.106447_bib35","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jinf.2025.106447_bib36","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1093\/infdis\/jiad508","article-title":"Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial","volume":"230","author":"Bennett","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2025.106447_bib37","doi-asserted-by":"crossref","unstructured":"McLeod C, Dymock M, Flanagan K, Plebanski M, Marshall HS, Estcourt MJ, et al. The Platform Trial in COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old: SSRN; 2024. Available from: \u3008http:\/\/dx.doi.org\/10.2139\/ssrn.4882412\u3009.","DOI":"10.2139\/ssrn.4882412"}],"updated-by":[{"DOI":"10.1016\/j.jinf.2026.106850","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T19:41:47Z","timestamp":1789328507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0163445325000416"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106447","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106447"}}